Chemours (CC) has kicked off Q1 2026 with revenue of US$1.4 billion, a basic EPS loss of US$0.19 and net income excluding extra items of a US$29 million loss, with trailing 12 month figures showing revenue of US$5.8 billion and a net loss of US$410 million or basic EPS of US$2.79. Over recent quarters the company has seen revenue move from US$1.37 billion in Q1 2025 to US$1.38 billion in Q4 2025 and now US$1.4 billion, while quarterly basic EPS has ranged from a loss of US$2.54 in Q2 2025 to a profit of US$0.40 in Q3 2025 before reverting to losses in Q4 2025 and Q1 2026. For investors, this mix of steady top line and recurring quarterly losses keeps the focus firmly on margins and on whether profitability can stabilise from here.

See our full analysis for Chemours.

With the headline numbers set, the next step is to see how these results line up against the widely held market and community narratives around Chemours, highlighting where the story is being confirmed and where it is being challenged.

Losses Persist As Trailing Net Income Sits At A US$410 Million Deficit

• On a trailing 12 month basis, Chemours reported total revenue of US$5.8b and a net loss excluding extra items of US$410 million, with basic EPS at a loss of US$2.79. This points to pressure on margins even as revenue has been relatively steady around the US$5.8b to US$5.9b range over the past six quarters.
• Bears focus on this pattern by arguing that earnings pressures and environmental overhangs could keep profitability under strain, and the recent run of losses gives them some support:
  • The trailing 12 month net loss of US$410 million compares with a small profit of US$10 million in the period ending Q1 2025. Critics highlight this as evidence that profitability has moved in the wrong direction over the last year.
  • Bears also point to five year earnings declines of 55.7% per year and the current loss in Q1 2026 of US$29 million as data points that make it harder for an earnings recovery argument to gain traction right now.

Revenue Growing 5.1% Per Year While Market Runs At 11.3%

• Over the last 12 months, Chemours' revenue has grown at 5.1% annually to around US$5.8b. This sits well below the cited US market growth rate of 11.3% per year, so the company is expanding more slowly than that broader benchmark.
• For bullish investors who expect faster growth from areas like Opteon and advanced materials, this gap sets up a clear test of their thesis:
  • Bulls argue that regulatory driven demand for low global warming potential refrigerants and specialty fluoropolymers could drive revenue growth well above 5%. However, the current 5.1% annual rate on trailing numbers has not reached those higher assumptions.
  • Supporters of the bullish narrative often point to electrification and capacity expansions as future drivers, while the latest quarterly revenue of US$1.38b shows a relatively tight range compared with US$1.33b to US$1.62b over recent quarters rather than the kind of acceleration they are looking for.

On that view, bulls who see Q1 as a stepping stone toward stronger growth may want to weigh these trailing figures against the more optimistic earnings path set out in the upbeat narrative before leaning too hard into it 🐂 Chemours Bull Case.

DCF Fair Value Of US$63.95 Vs Share Price Of US$23.67

• Chemours shares recently traded at US$23.67 while the provided DCF fair value is US$63.95, and the stock sits on a P/S of 0.6x compared with 1.1x for peers and the broader US Chemicals industry. The market is currently assigning a lower multiple than those reference points.
• Skeptics argue that this discount is not arbitrary and link it directly to balance sheet and earnings strain:
  • Trailing 12 month losses of US$410 million and a five year earnings decline of 55.7% per year are used by bears to argue that the weaker P/S multiple may simply reflect sustained profitability issues rather than a clear mispricing.
  • Critics also highlight that interest payments are not well covered by earnings and that the 1.48% dividend yield is not well covered either. They see these factors as reasons the stock might continue to trade below both the DCF fair value and the 23.22 analyst target being referenced.

For investors who see that valuation gap and wonder if caution is still warranted, it can be useful to read how skeptics connect the environmental and balance sheet risks to these discounts before making a call 🐻 Chemours Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Chemours on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With mixed signals on growth, earnings and valuation, it helps to move fast and check the underlying data for yourself before sentiment shifts again. To get a balanced view of both the key risks and the potential rewards that other investors are watching, start with these 2 key rewards and 3 important warning signs.

See What Else Is Out There

Chemours is working through recurring losses, weaker earnings coverage and slower 5.1% revenue growth, which together highlight meaningful pressure on both profitability and the balance sheet.

If you want alternatives where financial strength is more of a starting point than an open question, check out the solid balance sheet and fundamentals stocks screener (45 results) and see how those companies compare today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.